Citius Oncology, Inc.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On September 29, 2026, Citius Oncology, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, our stockholders elected the following Class II directors for a three-year term expiring at the annual meeting of stockholders to be held in 2029 or until their successors are duly elected and qualified, based on the following votes:

Next, our stockholders ratified the selection of Wolf & Company, P.C. as our independent registered public accounting firm for the fiscal year ended September 30, 2026. The vote for such ratification was 73,533,649 shares for, 8,809,478 shares against, 14,370 shares abstaining, and no broker non-votes.